Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune...

Full description

Saved in:
Bibliographic Details
Published in:Cell 2017-02, Vol.168 (4), p.707-723
Main Authors: Sharma, Padmanee, Hu-Lieskovan, Siwen, Wargo, Jennifer A., Ribas, Antoni
Format: Article
Language:English
Subjects:
Animals
Drug Therapy, Combination
Humans
Immunotherapy
Molecular Targeted Therapy
Neoplasms - immunology
Neoplasms - therapy
resistance mechanisms
T cells
T-Lymphocytes - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients. Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
ISSN:0092-8674
1097-4172
DOI:10.1016/j.cell.2017.01.017